|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001779,
umls-concept:C0007131,
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0205179,
umls-concept:C0205390,
umls-concept:C0246415,
umls-concept:C0439234,
umls-concept:C0684249,
umls-concept:C1122962,
umls-concept:C1708063
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-4-28
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
This is a phase 2 study of chemotherapy-naive patients, 70 years of age or older, with nonsmall-cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:AntoniaScott JSJ,
pubmed-author:BegumMubeenaM,
pubmed-author:BeplerGeroldG,
pubmed-author:ChiapporiAlbertoA,
pubmed-author:ExtermannMartineM,
pubmed-author:HauraEric BEB,
pubmed-author:Ismail-KhanRoohiR,
pubmed-author:KapoorRachnaR,
pubmed-author:SchellMichael JMJ,
pubmed-author:SimonGeorge RGR,
pubmed-author:WilliamsCharles CCC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
112
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2021-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18300255-Activities of Daily Living,
pubmed-meshheading:18300255-Aged,
pubmed-meshheading:18300255-Aged, 80 and over,
pubmed-meshheading:18300255-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18300255-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18300255-Comorbidity,
pubmed-meshheading:18300255-Female,
pubmed-meshheading:18300255-Humans,
pubmed-meshheading:18300255-Lung Neoplasms,
pubmed-meshheading:18300255-Male,
pubmed-meshheading:18300255-Mutation,
pubmed-meshheading:18300255-Quinazolines,
pubmed-meshheading:18300255-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18300255-Taxoids
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
|
|
pubmed:affiliation |
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. george.simon@moffitt.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
